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Despite recent advances in basic and translational 
research in the field of cutaneous lymphomas (1, 2), ef-
fective treatment options for advanced mycosis fungoides 
(MF) and Sézary syndrome (SS) are limited. Conventio-
nal therapies usually result only in short-lived remission 
(3), lacking any long-term advantage of more aggres-
sive chemotherapeutic regimens (4) and having septic 
complications. A recent retrospective meta-analysis 
found that immunological treatment approaches, such 
as interferon or extracorporeal photopheresis, as well 
as epigenetic modifiers, produce better rates of disease 
control in patients with MF and SS than does immuno-
suppressive chemotherapy (5). Hence, better immunomo-
dulating drugs addressing the tumour microenvironment 
of cutaneous lymphomas (6) as well as novel targeted 
therapies and innovative combinational approaches (7) 
are urgently required (8).
We report here a patient with SS and nodal CD30-
positive manifestation who was treated with a combina-
tion of extracorporeal photopheresis (ECP) and the drug-
conjugated anti-CD30 antibody brentuximab vedotin. 
CASE REPORT
The 77-year-old man was diagnosed with SS in February 2011. 
Due to extensive erythroderma and blood manifestation (elevated 
lactate dehydrogenase > 500 U/l and a CD4/CD8 ratio > 100 with 
antigen loss of CD7 and CD26), lymph node and bone marrow 
involvement (stage IVA2 of the ISCL/EORTC classification), 
he underwent multiple systemic treatments. At first, the patient 
was treated with methotrexate, 15 mg/week, which was changed 
to bexarotene, gemcitabine and chlorambucil/prednisolone after 
only short-lived remissions and subsequent therapeutic failure, 
respectively. Rapid progression of skin lesions led us to apply total 
skin electron beam radiation therapy, but without success, so that 
3 months later a dual LSD1-(lysine-specific demethylase)/HDAC- 
(histone deacetylase) inhibitor-inhibitor was started within a phase 
I study. Owing to further disease progression, treatment was 
changed after another 3 months to liposomal doxorubicin, under 
which the patient encountered multiple complications including 
bullous palmoplantar erythrodysaesthesia and serious bacterial 
infections. Finally, 46 months after the first diagnosis and after ha-
ving undergone 6 prior and, in the long run, unsuccessful, systemic 
treatment modalities, chosen according to international standards, 
the patient presented with acute thrombosis on the left iliac vein 
due to compression by rapidly progressive inguinal and pelvic 
lymph nodes. Clinical examination and computed tomography 
(CT) scan revealed multiple enlarged 
lymph nodes (Fig. 1a). As biopsy of 
an enlarged lymph node showed nodal 
CD30-positive lymphoma infiltration 
(Fig. 1b), we decided to initiate treat-
ment with brentuximab vedotin within 
an off-label setting after obtaining the 
patient’s consent. At this time-point, 
blood and skin manifestations showed 
partial expression of CD30 in 5–10% 
of lymphoma cells before initiation of 
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Fig. 1. Clinical and histologic features. 
(a) Progressive enlarged ilioinguinal lymph 
nodes are present before treatment start with 
brentuximab vedotin. (b) Histology of an excised 
inguinal lymph node shows diffuse infiltration of 
T-cell lymphoma with large cell transformation 
(haematoxylin and eosin (HE) ×200). Expression 
of CD30 in at least 10% of lymphoma cells is 
present within the lymph node (CD30 staining 
×200) (insert). (c) Progressive skin disease 
with infiltrated, papular erythroderma was 
present 4 months after initiation of brentuximab 
vedotin (5 cycles). (d) Histology of skin shows 
an epidermotropic atypical T-cell infiltrate of 
medium-sized cerebriform lymphoma cells 
with indented nuclei (HE × 200). Neoplastic T 
cells of the skin are negative for CD30 (CD30 


























































brentuximab vedotin. Rapid partial remission of nodal disease, 
decline in blood tumour burden and initial amelioration of cu-
taneous manifestations was achieved under this treatment regi-
men. However, after 4 months of treat ment, progressive pruritic 
papular infiltration of the skin with worsened erythroderma again 
developed (Fig. 1c). Of note, blood and skin manifestations were 
now repetitively negative for CD30 (Fig. 1d) despite continued 
tracking of the identical T-cell clone in respective compartments. 
This finding led us to choose an add-on treatment with ECP. 
Over a period of 8 consecutive months the patient received 
combination therapy with intravenous brentuximab vedotin, 1.8 
mg/m2, every 3 weeks and ECP on 2 consecutive days every 
4–6 weeks. Lymph nodes returned to almost normal size and the 
cutaneous tumour burden improved significantly after the addi-
tion of ECP with almost resolution of confluent erythroderma 
and novel, steadily enlarging “nappes claires” corresponding to 
clinically uninvolved skin (Fig. S1a, b1). Moreover, since the start 
of treatment with brentuximab vedotin the lactate dehydrogenase 
levels returned to 300–400 U/l, albeit exhibiting an undulating 
course without strict correlation with clinical response and the 
CD4/CD8 ratio in peripheral blood declined significantly from 
pre-therapeutic levels of 195 vs. lowest levels of 45, the latter 
especially after the addition of ECP to the therapeutic regimen 
(Fig. S1c1). Undulating and minor paraesthetic sensations in the 
legs were managed successfully by intermittent increase in dose 
intervals of brentuximab vedotin to 4 weeks, as initial neuropa-
thy could not be excluded with certainty; otherwise, the patient 
did not experience any serious (> grade 2) complications like 
neutropaenia, sensorimotor neuropathy or infections under this 
treatment and presented with a good quality of life. However, 16 
months after the start of brentuximab vedotin and 8 months after 
initiation of combination therapy, ECP was discontinued due to 
repetitive failure to achieve sufficient vascular access and further 
refusal by the patient. After discontinuation of this combined 
treatment, blood and skin manifestations were rapidly progres-
sive and refractory to next-line treatment with bendamustine and 
the patient died 9 months after discontinuation of brentuximab 
vedotin/ECP treatment.
DISCUSSION
A better understanding and more detailed characteriza-
tion of the immunophenotypic and molecular genetic 
features of systemic lymphomas has paved the way for 
the development of more specific and better tolerated 
anti-neoplastic drugs (2, 7). In this respect, the common 
expression of CD30 in Hodgkin’s lymphoma, as well 
as in systemic anaplastic large-cell lymphoma, can be 
targeted by immunotherapeutic approaches. This has 
led to the approval of the drug-conjugated anti-CD30 
antibody brentuximab vedotin-monomethyl auristatin E 
for treatment of relapsed or refractory disease condition 
in European countries (9). Beside primary cutaneous 
CD30-positive lymphoproliferative disorders, expres-
sion of CD30 may also be observed in advanced MF 
and, rarely, in SS, especially within the context of large 
cell transformation (10). However, CD30-positive cells 
in MF and SS are usually present to a more variable and, 
altogether lower, extent and are often not universally 
found in all affected disease compartments, such as skin, 
blood, lymph nodes or viscera. Nevertheless, several 
case reports for SS (11–13) and a recent phase II clinical 
study evaluating brentuximab vedotin in MF and SS have 
demonstrated high efficacy (14), and a phase III trial is 
in progress (ALCANZA trial; https://ash.confex.com/
ash/2016/webprogram/Paper91517.html). Of note, the 
response was rather irrespective of the level of CD30 
expression in lymphoma tissue, hinting at possible ad-
ditional bystander-effects of the drug within the tumour 
microenvironment (15). Based on these promising clini-
cal data, we treated our patient with brentuximab vedotin 
in an off-label setting. Owing to prior, life-threatening 
infectious complications in our patient, and a putative risk 
of neutropaenia under brentuximab vedotin, an add-on 
therapy with non-immunosuppressive ECP was chosen 
for CD30-negative non-responsive manifestations. Se-
veral topical or systemic combination modalities have 
been evaluated in conjunction with ECP, with additional 
therapeutic success (16). However, to date, there are no 
reports on such a multimodal approach combining ECP 
with brentuximab vedotin for SS and, altogether, only 
a few patients with SS have been reported to be treated 
successfully with brentuximab vedotin monotherapy. 
Therefore, our approach is new, in combining the 
rather unspecific immunomodulating treatment effects 
of ECP with a compartment-directed targeted therapy 
and thus exploiting super-additive therapeutic effects 
with distinct kinetics, producing both rapid and long-
term response.
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